Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

Atara Biotherapeutics (ATRA) Leases (2022 - 2025)

Atara Biotherapeutics (ATRA) has disclosed Leases for 4 consecutive years, with $10.7 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Leases fell 76.64% year-over-year to $10.7 million, compared with a TTM value of $10.7 million through Sep 2025, down 76.64%, and an annual FY2024 reading of $39.8 million, down 27.54% over the prior year.
  • Leases was $10.7 million for Q3 2025 at Atara Biotherapeutics, down from $11.0 million in the prior quarter.
  • Across five years, Leases topped out at $73.6 million in Q2 2022 and bottomed at $10.7 million in Q3 2025.
  • Average Leases over 4 years is $48.8 million, with a median of $52.0 million recorded in 2024.
  • The sharpest move saw Leases surged 244.07% in 2023, then crashed 77.47% in 2025.
  • Year by year, Leases stood at $68.0 million in 2022, then dropped by 19.24% to $54.9 million in 2023, then decreased by 27.54% to $39.8 million in 2024, then crashed by 73.1% to $10.7 million in 2025.
  • Business Quant data shows Leases for ATRA at $10.7 million in Q3 2025, $11.0 million in Q2 2025, and $50.8 million in Q1 2025.